Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099852 | 0.85 | MIF (0.45) | MIFHPGDKDM4ELMNAP2RX7 | |
| SCHEMBL1751960 | 0.83 | F10 (0.49) | F10 | |
| SCHEMBL8166637 | 0.82 | MIF (0.45) | MIFHPGDNOTUMKDM4ELMNA | |
| SCHEMBL8160461 | 0.82 | MIF (0.45) | MIFHPGDNOTUMKDM4ELMNA | |
| SCHEMBL1106557 | 0.79 | MIF (0.61) | MIFHPGDNOTUMKDM4ELMNA | |
| SCHEMBL3087689 | 0.77 | MIF (0.48) | MIFHPGDNOTUMEPHX2 | |
| SCHEMBL1106568 | 0.73 | MIF (0.43) | MIFHPGDKDM4ELMNAP2RX7 | |
| SCHEMBL8278997 | 0.73 | MIF (0.43) | MIFHPGDKDM4ELMNAP2RX7 | |
| SCHEMBL1095795 | 0.72 | MIF (0.44) | MIFHPGDNOTUMP2RX7F10 | |
| SCHEMBL1752041 | 0.72 | F10 (0.51) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160196-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293704-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008086226-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293704-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | MIF 837/4885HPGD 429/4885NOTUM 361/4885 |
| US-20110160196-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | MIF 837/4885HPGD 429/4885NOTUM 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.